News
RARE
44.46
-1.51%
-0.68
Weekly Report: what happened at RARE last week (0708-0712)?
Weekly Report · 11h ago
What Led To A 150% Rise In uniQure Stock In A Week?
NASDAQ · 18h ago
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Abeona Therapeutics Inc.'s BLA resubmission of Pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa is expected 2nd half of 2024. If approved by the FDA, the company believes that it could reach peak U.S. Sales of >$500 million by year 5 of the gene therapy being sold. Abeona has already licensed out other gene therapies in its pipeline.
Seeking Alpha · 3d ago
Morgan Stanley Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 3d ago
Bullish Two Hundred Day Moving Average Cross - RARE
NASDAQ · 5d ago
Weekly Report: what happened at RARE last week (0701-0705)?
Weekly Report · 07/08 09:24
Weekly Report: what happened at RARE last week (0624-0628)?
Weekly Report · 07/01 09:24
Mereo BioPharma: Positioned For Potential Breakthroughs
Mereo BioPharma Group plc has seen a rebound in its stock over the past year. The company is focused on developing therapeutics for oncology and rare diseases. Mereo has a lead candidate for Osteogenesis Imperfecta, a rare affliction. The stock has multiple drug candidates in development and a positive analyst outlook.
Seeking Alpha · 06/30 13:25
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
Benzinga · 06/27 15:39
Weekly Report: what happened at RARE last week (0617-0621)?
Weekly Report · 06/24 09:26
Ultragenyx Shareholders Approve Directors and Incentive Plans
TipRanks · 06/21 21:10
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. Granted 45,525 restricted stock units to 26 newly hired non-executive officers of the company. The company is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases.
Barchart · 06/20 15:30
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Piper Sandler
TipRanks · 06/20 11:35
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), 908 Devices (MASS) and Nurix Therapeutics (NRIX)
TipRanks · 06/17 09:50
TD Cowen Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks · 06/17 09:50
Weekly Report: what happened at RARE last week (0610-0614)?
Weekly Report · 06/17 09:24
Chief Legal Officer & Executive VP of Corporate Affairs Of Ultragenyx Pharmaceutical Sold 39% Of Their Shares
Ultragenyx Pharmaceutical Inc. Insiders sold US$441k worth of shares in the last 12 months. The company doesn't have any big insider purchases over the last year. Insiders own 3.0% of the company, but sold shares at a lower price than the current share price. It is good to see an insider sale of shares, but the level of insider selling leaves us cautious. Ultragenyx pharmaceutical is not a good stock to buy right now. Simply Wall St looks at insider buying and selling of Ultrageny Pharmaceutical.
Simply Wall St · 06/16 12:20
Analysts’ Top Healthcare Picks: Intra-Cellular Therapies (ITCI), Gilead Sciences (GILD)
Intra-Cellular Therapies (ITCI – Research Report), Gilead Sciences (GILD) and Ultragenyx Pharmaceutical (RARE) have bullish sentiments. 3 analysts have maintained Buy ratings on the 3 Healthcare sector stocks. Intra- cellulartherapies has an analyst consensus of Strong Buy, with a $94.31 price target.
TipRanks · 06/16 12:14
RPT-BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Hasbro, VinFast
U.S. Stock indexes fall on Friday. Nasdaq and S&P 500 slip from record highs. Investors booked profits and weighed hawkish Fed projections against slowing economic data. The Dow Jones Industrial Average was down 0.27% and the Nasdaq Composite was up 0.11%.
Reuters · 06/14 18:35
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session. AMMO reported a fourth-quarter profit of 1 cent per share. The company reported quarterly sales of $40.42 million. Kaival Brands Innovations Group, Inc (KAVL) shares jumped 345% to $6.06.
Benzinga · 06/14 18:13
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.